The Claim
In adults with type 1 diabetes, insulin glargine U300 reduces 24-hour β-hydroxybutyrate concentrations by approximately 28% (0.72 mmol/L, 90% CI 0.58–0.90) compared to insulin glargine U100 under euglycemic clamp conditions.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 1 diabetes, insulin glargine U300 lowers blood levels of β-hydroxybutyrate by about 28% compared to insulin glargine U100 when blood glucose is held at normal levels.
See the scientific wording
In adults with type 1 diabetes, insulin glargine U300 reduces 24-hour β-hydroxybutyrate concentrations by approximately 28% (0.72 mmol/L, 90% CI 0.58–0.90) compared to insulin glargine U100, indicating greater suppression of ketogenesis under euglycemic clamp conditions.
A longer-lasting form of insulin keeps blood insulin levels steady for more hours, which tells the pancreas to release less glucagon. Lower glucagon stops the liver from breaking down stored fat and making ketones. With less fat being released from fat tissue, the liver has less fuel to produce ketones, so ketone levels in the blood drop.
What the research says
1 studyIn people with type 1 diabetes, a longer-lasting form of insulin called glargine U300 was shown to lower ketone levels more than the older version, glargine U100—even when blood sugar was kept steady. This means U300 is better at stopping the liver from making ketones.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.